The main objective of the DAHLIAS project is to optimise hybrid joining (Refill Friction Stir Spot Welding, RFSSW, with an adhesive sealant bond) for application in aircraft structures. RFSSW is a solid-state joining technology especially applicable to lightweight alloys in similar and dissimilar configurations. The process has been successfully applied to difficult-to-weld and non-weldable alloys and is considered a potential replacement of mechanical fastening. Overlap joints in aircraft structures require the use of sealants for corrosion protection reasons. Using sealants with an adhesive function would complement the high quality joints produced by RFSSW by not only protecting against corrosion but also contributing to the overall mechanical performance of the structure. To achieve the main goal of this project a work plan consisting of eight work packages has been devised. Two work packages are focused on the RFSSW process development using standard samples with and without adhesive sealant. In parallel the adhesive sealant technology, including surface pre-treatment will be developed. The hybrid joining solution developed in this project will be compared to conventional joining technologies to define its potential. Hybrid joining brings a number of advantages to production and performance of aircraft structures. The change from differential to integral design introduces new challenges in the analysis of mechanical performance. Hence, the damage tolerance behaviour of hybrid joints is also investigated in this project. Quality control methods will be investigated by selecting NDT methods and by process control based on online monitoring of parameters. In the last phase of this project technology demonstrators will be produced to evaluate the capabilities of the proposed technology in actual aircraft structures. The consortium (3 R&D and 2 industrial partners) has the exact fitting, prooven expertise and high excellence. HZG (coordinator) holds key patents.

Currently Thailand clearly lacks in capacities to supply the beverage industry with adequately trained students and qualified non-academic staff. There are either technical engineers with technical knowledge & skills, but lacking of deeper knowledge on food quality, hygiene, production processes, etc., or food scientists, less skilled in engineering and without deeper knowledge in beverage technology. Now the Thai beverage industry trains their employees in house or in a limited number by Universities or overseas. The last option is only possible for few selected employees. A proper structured and sustainable collaborative concept for high quality continuing professional development (CPD) training for beverage technology is not established.To overcome these gaps a consortium of Thai and EU universities and companies of the beverage industry will establish systematically an independent joint Academy, with hubs in Thailand and EU, to enable a new sustainable collaboration between the partners for a continuing needs analysis, for developing new demand driven educational products using innovative pedagogical approaches and teaching tools to be used in CPD and higher Education (HE). Special emphasis will be given also to hygiene and environmental aspects and skills like teamwork, critical thinking and English language. The developed educational products will be qualified according international standards and implemented in a postgraduate master, in existing curricula to have an optional focus in beverage technology with the option for double/joint degrees with EU universities. Further the Academy will establish a high quality and certified LLL program using existing facilities and a certification scheme for different profiles like quality and safety manager, brewing technologist, wine technologist, etc.With the postgraduate education and the CPD training an impact will be achieved both in short time as well long term with the tuned curricula.

This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project. The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer. NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities: • Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process. • Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD). This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).